Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
Identifieur interne : 003052 ( PubMed/Curation ); précédent : 003051; suivant : 003053Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
Auteurs : Anthony H. Barnett [France] ; Bernard Charbonnel [France] ; Robert G. Moses [Australie] ; Sanjay Kalra [Inde]Source :
- Current medical research and opinion [ 1473-4877 ] ; 2015.
Descripteurs français
- KwdFr :
- Diabète de type 2 (traitement médicamenteux), Glycémie (), Humains, Hypoglycémiants (administration et posologie), Hypoglycémie (), Inhibiteurs de la dipeptidyl-peptidase IV (administration et posologie), Inhibiteurs de la dipeptidyl-peptidase IV (effets indésirables), Insuline (usage thérapeutique), Sulfonylurées (administration et posologie).
- MESH :
- administration et posologie : Hypoglycémiants, Inhibiteurs de la dipeptidyl-peptidase IV, Sulfonylurées.
- effets indésirables : Inhibiteurs de la dipeptidyl-peptidase IV.
- traitement médicamenteux : Diabète de type 2.
- usage thérapeutique : Insuline.
- Glycémie, Humains, Hypoglycémie.
English descriptors
- KwdEn :
- Blood Glucose (drug effects), Diabetes Mellitus, Type 2 (drug therapy), Dipeptidyl-Peptidase IV Inhibitors (administration & dosage), Dipeptidyl-Peptidase IV Inhibitors (adverse effects), Humans, Hypoglycemia (chemically induced), Hypoglycemic Agents (administration & dosage), Insulin (therapeutic use), Sulfonylurea Compounds (administration & dosage).
- MESH :
- chemical , administration & dosage : Dipeptidyl-Peptidase IV Inhibitors, Hypoglycemic Agents, Sulfonylurea Compounds.
- chemical , adverse effects : Dipeptidyl-Peptidase IV Inhibitors.
- chemical , drug effects : Blood Glucose.
- chemically induced : Hypoglycemia.
- drug therapy : Diabetes Mellitus, Type 2.
- chemical , therapeutic use : Insulin.
- Humans.
Abstract
There is no clear consensus regarding treatment of patients with type 2 diabetes mellitus (T2DM) that is inadequately controlled using dual combination therapy. Recommended agents for triple combination therapy should have complementary mechanisms of action with minimal risk of added side effects such as weight gain and hypoglycemia. We discuss considerations in selecting triple oral therapy regimens in patients with T2DM, and review clinical trial data regarding triple oral therapy using dipeptidyl peptidase-4 (DPP-4) inhibitors.
DOI: 10.1185/03007995.2015.1081589
PubMed: 26361231
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003149
Links to Exploration step
pubmed:26361231Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.</title><author><name sortKey="Barnett, Anthony H" sort="Barnett, Anthony H" uniqKey="Barnett A" first="Anthony H" last="Barnett">Anthony H. Barnett</name><affiliation wicri:level="1"><nlm:affiliation>a a Heart of England NHS Foundation Trust and University of Birmingham, Birmingham, UK , Nantes , France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>a a Heart of England NHS Foundation Trust and University of Birmingham, Birmingham, UK , Nantes </wicri:regionArea></affiliation></author><author><name sortKey="Charbonnel, Bernard" sort="Charbonnel, Bernard" uniqKey="Charbonnel B" first="Bernard" last="Charbonnel">Bernard Charbonnel</name><affiliation wicri:level="1"><nlm:affiliation>b b Centre Hospitalier, Universitaire de Nantes , Nantes , France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>b b Centre Hospitalier, Universitaire de Nantes , Nantes </wicri:regionArea></affiliation></author><author><name sortKey="Moses, Robert G" sort="Moses, Robert G" uniqKey="Moses R" first="Robert G" last="Moses">Robert G. Moses</name><affiliation wicri:level="1"><nlm:affiliation>c c Illawarra Diabetes Service, South East Sydney & Illawarra Area Health Service , Wollongong , Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>c c Illawarra Diabetes Service, South East Sydney & Illawarra Area Health Service , Wollongong </wicri:regionArea></affiliation></author><author><name sortKey="Kalra, Sanjay" sort="Kalra, Sanjay" uniqKey="Kalra S" first="Sanjay" last="Kalra">Sanjay Kalra</name><affiliation wicri:level="1"><nlm:affiliation>d d Bharti Hospital and Bharti Research Institute of Diabetes and Endocrinology , Kamal , India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>d d Bharti Hospital and Bharti Research Institute of Diabetes and Endocrinology , Kamal </wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26361231</idno><idno type="pmid">26361231</idno><idno type="doi">10.1185/03007995.2015.1081589</idno><idno type="wicri:Area/PubMed/Corpus">003149</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003149</idno><idno type="wicri:Area/PubMed/Curation">003052</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003052</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.</title><author><name sortKey="Barnett, Anthony H" sort="Barnett, Anthony H" uniqKey="Barnett A" first="Anthony H" last="Barnett">Anthony H. Barnett</name><affiliation wicri:level="1"><nlm:affiliation>a a Heart of England NHS Foundation Trust and University of Birmingham, Birmingham, UK , Nantes , France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>a a Heart of England NHS Foundation Trust and University of Birmingham, Birmingham, UK , Nantes </wicri:regionArea></affiliation></author><author><name sortKey="Charbonnel, Bernard" sort="Charbonnel, Bernard" uniqKey="Charbonnel B" first="Bernard" last="Charbonnel">Bernard Charbonnel</name><affiliation wicri:level="1"><nlm:affiliation>b b Centre Hospitalier, Universitaire de Nantes , Nantes , France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>b b Centre Hospitalier, Universitaire de Nantes , Nantes </wicri:regionArea></affiliation></author><author><name sortKey="Moses, Robert G" sort="Moses, Robert G" uniqKey="Moses R" first="Robert G" last="Moses">Robert G. Moses</name><affiliation wicri:level="1"><nlm:affiliation>c c Illawarra Diabetes Service, South East Sydney & Illawarra Area Health Service , Wollongong , Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>c c Illawarra Diabetes Service, South East Sydney & Illawarra Area Health Service , Wollongong </wicri:regionArea></affiliation></author><author><name sortKey="Kalra, Sanjay" sort="Kalra, Sanjay" uniqKey="Kalra S" first="Sanjay" last="Kalra">Sanjay Kalra</name><affiliation wicri:level="1"><nlm:affiliation>d d Bharti Hospital and Bharti Research Institute of Diabetes and Endocrinology , Kamal , India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>d d Bharti Hospital and Bharti Research Institute of Diabetes and Endocrinology , Kamal </wicri:regionArea></affiliation></author></analytic><series><title level="j">Current medical research and opinion</title><idno type="eISSN">1473-4877</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blood Glucose (drug effects)</term><term>Diabetes Mellitus, Type 2 (drug therapy)</term><term>Dipeptidyl-Peptidase IV Inhibitors (administration & dosage)</term><term>Dipeptidyl-Peptidase IV Inhibitors (adverse effects)</term><term>Humans</term><term>Hypoglycemia (chemically induced)</term><term>Hypoglycemic Agents (administration & dosage)</term><term>Insulin (therapeutic use)</term><term>Sulfonylurea Compounds (administration & dosage)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Diabète de type 2 (traitement médicamenteux)</term><term>Glycémie ()</term><term>Humains</term><term>Hypoglycémiants (administration et posologie)</term><term>Hypoglycémie ()</term><term>Inhibiteurs de la dipeptidyl-peptidase IV (administration et posologie)</term><term>Inhibiteurs de la dipeptidyl-peptidase IV (effets indésirables)</term><term>Insuline (usage thérapeutique)</term><term>Sulfonylurées (administration et posologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dipeptidyl-Peptidase IV Inhibitors</term><term>Hypoglycemic Agents</term><term>Sulfonylurea Compounds</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dipeptidyl-Peptidase IV Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Blood Glucose</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Hypoglycémiants</term><term>Inhibiteurs de la dipeptidyl-peptidase IV</term><term>Sulfonylurées</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hypoglycemia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Diabetes Mellitus, Type 2</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Inhibiteurs de la dipeptidyl-peptidase IV</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Insulin</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Diabète de type 2</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Insuline</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Glycémie</term><term>Humains</term><term>Hypoglycémie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There is no clear consensus regarding treatment of patients with type 2 diabetes mellitus (T2DM) that is inadequately controlled using dual combination therapy. Recommended agents for triple combination therapy should have complementary mechanisms of action with minimal risk of added side effects such as weight gain and hypoglycemia. We discuss considerations in selecting triple oral therapy regimens in patients with T2DM, and review clinical trial data regarding triple oral therapy using dipeptidyl peptidase-4 (DPP-4) inhibitors.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26361231</PMID><DateCreated><Year>2015</Year><Month>09</Month><Day>22</Day></DateCreated><DateCompleted><Year>2016</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2015</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1473-4877</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>10</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>Current medical research and opinion</Title><ISOAbbreviation>Curr Med Res Opin</ISOAbbreviation></Journal><ArticleTitle>Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.</ArticleTitle><Pagination><MedlinePgn>1919-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1185/03007995.2015.1081589</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">There is no clear consensus regarding treatment of patients with type 2 diabetes mellitus (T2DM) that is inadequately controlled using dual combination therapy. Recommended agents for triple combination therapy should have complementary mechanisms of action with minimal risk of added side effects such as weight gain and hypoglycemia. We discuss considerations in selecting triple oral therapy regimens in patients with T2DM, and review clinical trial data regarding triple oral therapy using dipeptidyl peptidase-4 (DPP-4) inhibitors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A search of the PubMed database was conducted to identify clinical trials of triple oral therapy incorporating a DPP-4 inhibitor (November 2013 to January 2015), using the following search terms: 'type 2 diabetes' AND 'alogliptin OR linagliptin OR saxagliptin OR sitagliptin OR vildagliptin' AND 'metformin'. Trials had to include adult patients with T2DM who received triple oral therapy with a DPP-4 inhibitor for ≥18 weeks. The bibliographies of retrieved articles were also searched to identify any other relevant trials.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 17 clinical trials evaluating metformin and a DPP-4 inhibitor combined with a sulfonylurea (SU), thiazolidinedione (TZD), or sodium-glucose cotransporter 2 (SGLT2) inhibitor were identified and included in this review. Consistently, the addition of a DPP-4 inhibitor to metformin and SU, TZD, or SGLT2 inhibitor therapy improved glycemic measures, and these combinations were generally well tolerated. An increased incidence of hypoglycemia was reported for combinations that included an SU.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Triple oral therapy that includes a DPP-4 inhibitor is a valid option for patients with T2DM not adequately controlled with dual combination therapy, and offers an alternative to insulin therapy. Triple oral therapy with a DPP-4 inhibitor, metformin, and a TZD or SGLT2 inhibitor should be considered when avoidance of hypoglycemia is a primary goal.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barnett</LastName><ForeName>Anthony H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>a a Heart of England NHS Foundation Trust and University of Birmingham, Birmingham, UK , Nantes , France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charbonnel</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>b b Centre Hospitalier, Universitaire de Nantes , Nantes , France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moses</LastName><ForeName>Robert G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>c c Illawarra Diabetes Service, South East Sydney & Illawarra Area Health Service , Wollongong , Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalra</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>d d Bharti Hospital and Bharti Research Institute of Diabetes and Endocrinology , Kamal , India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Med Res Opin</MedlineTA><NlmUniqueID>0351014</NlmUniqueID><ISSNLinking>0300-7995</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013453">Sulfonylurea Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054873" MajorTopicYN="N">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007003" MajorTopicYN="N">Hypoglycemia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013453" MajorTopicYN="N">Sulfonylurea Compounds</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antihyperglycemic therapy</Keyword><Keyword MajorTopicYN="N">Combination therapy</Keyword><Keyword MajorTopicYN="N">Dipeptidyl peptidase-4 inhibitor</Keyword><Keyword MajorTopicYN="N">Hypoglycemia</Keyword><Keyword MajorTopicYN="N">Incretin</Keyword><Keyword MajorTopicYN="N">Oral therapy</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes mellitus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26361231</ArticleId><ArticleId IdType="doi">10.1185/03007995.2015.1081589</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003052 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003052 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:26361231
|texte= Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26361231" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |